title: Three-year follow-up of hydroxyurea treatment in severely ill children with sickle cell disease. The French Study Group on Sickle Cell Disease.
abstract: OBJECTIVE
  To observe the safety and efficacy of hydroxyurea (HU), a drug that stimulates fetal hemoglobin (Hb F) production, in previously severely ill children with sickle cell disease.
  
  
  METHODS
  HU was given in an uncontrolled study to 35 children with sickle cell disease, aged from 3 to 20 years, suffering from frequent painful crises. Mean duration of treatment was 32 months (range: 12-59 months).
  
  
  RESULTS
  HU induced an increase in Hb F levels in all children out one; this increase was maximal after 9 months of treatment, was largely sustained thereafter, and was related to HU dose and inversely to patients' age. We also noted an apparent reduction in crisis, which occurred principally after 3 months of therapy and did not seem strictly correlated with the rise in Hb F level. No serious hematopoietic complication was observed. Growth curves and sexual development were not modified.
  
  
  CONCLUSIONS
  Our data support the efficacy of HU in reducing painful events in children with sickle cell disease. Short- and middle-term tolerances are good. Thus, we think that HU can be given to children affected by frequent and severe painful crises. We recommend, however, very cautious use of this drug, because its long-term effects in children are still unknown.
authors.affiliation: Centre de Transfusion Sanguine, Hôpital Necker, Paris.
authors.forename: M
authors.initials: M
authors.lastname: de Montalembert
authors.forename: M
authors.initials: M
authors.lastname: Belloy
authors.forename: F
authors.initials: F
authors.lastname: Bernaudin
authors.forename: F
authors.initials: F
authors.lastname: Gouraud
authors.forename: R
authors.initials: R
authors.lastname: Capdeville
authors.forename: R
authors.initials: R
authors.lastname: Mardini
authors.forename: N
authors.initials: N
authors.lastname: Philippe
authors.forename: J P
authors.initials: JP
authors.lastname: Jais
authors.forename: J
authors.initials: J
authors.lastname: Bardakdjian
authors.forename: R
authors.initials: R
authors.lastname: Ducrocq
authors.forename: M
authors.initials: M
authors.lastname: Maier-Redelsperger
authors.forename: J
authors.initials: J
authors.lastname: Elion
authors.forename: D
authors.initials: D
authors.lastname: Labie
authors.forename: R
authors.initials: R
authors.lastname: Girot
mesh_terms: D000293:Adolescent; D000328:Adult; D000755:Anemia, Sickle Cell / Q000097:blood / Q000188:drug therapy*; D000986:Antisickling Agents / Q000009:adverse effects / Q000627:therapeutic use*; D056486:Chemical and Drug Induced Liver Injury; D002648:Child; D002675:Child, Preschool; D005260:Female; D005319:Fetal Hemoglobin / Q000378:metabolism; D005500:Follow-Up Studies; D006128:Growth / Q000187:drug effects; D006197:Hair / Q000187:drug effects; D006454:Hemoglobins / Q000378:metabolism; D006801:Humans; D006918:Hydroxyurea / Q000009:adverse effects / Q000627:therapeutic use*; D017495:Hyperpigmentation / Q000139:chemically induced; D007674:Kidney Diseases / Q000139:chemically induced; D008297:Male; D009260:Nail Diseases / Q000139:chemically induced; D011627:Puberty / Q000187:drug effects
chemical_list: D000986:Antisickling Agents; D006454:Hemoglobins; D005319:Fetal Hemoglobin; D006918:Hydroxyurea